Prospective Study Evaluating the Association Between sFlt-1/PlGF Ratio and Adverse Outcomes in Preterm Preeclampsia.

Objectives: To estimate the association between maternal soluble Fms tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF) ratio and adverse outcomes related to preterm preeclampsia.

Methods: We performed a prospective study including participants with preeclampsia between 24 and 36 weeks of gestation. The sFlt-1/PlGF ratio was measured in maternal serum at admission and was reported according to pregnancy outcomes (delivery in <7 days after admission, severe preeclampsia before term, and serious complications, including stillbirth; eclampsia; hemolysis, elevated liver enzymes, and low platelet syndrome; and acute renal failure).